Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
- Status
- AVAILABLE
- Phase
- N/A
Clinical Trials Related to Hepatocellular Carcinoma
Related studies linked through entity extraction aliases.
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
- Status
- UNKNOWN
- Phase
- PHASE1
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial
- Status
- COMPLETED
- Phase
- PHASE4
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Cytokine Change in Hepatocellular Carcinoma Treated by Thermal Ablation
- Status
- COMPLETED
- Phase
- NA
Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- N/A
Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment
- Status
- UNKNOWN
- Phase
- N/A
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
- Status
- UNKNOWN
- Phase
- PHASE1
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
HepATocellular Cancer Hcv Therapy Study
- Status
- WITHDRAWN
- Phase
- PHASE3
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
- Status
- TERMINATED
- Phase
- PHASE2
TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial
- Status
- UNKNOWN
- Phase
- NA
Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Liver Disease and Other Systemic Diseases
- Status
- RECRUITING
- Phase
- N/A
Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- NA
A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells
- Status
- UNKNOWN
- Phase
- NA
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3